News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Lifeblood Medical, Inc. Establishes Wholly Owned Subsidiary

9/6/2006 9:10:54 AM

FREEHOLD, N.J., Sept. 6 /PRNewswire/ -- Lifeblood Medical, Inc. has established Cell Preservation Solutions, LLC. The wholly owned subsidiary will conduct research and development on Lifeblood Medical's proprietary solution to enhance the technology for innovative applications.

"It is important for Lifeblood Medical to focus on the FDA approval process of Lifor® for organ transplantation," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical, Inc. "However, I feel it is also important that if we have a proprietary solution that can improve a multitude of preservation applications to get that product-use to market, so to this end Cell Preservation Solutions will begin research."

Mr. Fischer continued, "We will begin our research and development efforts to optimize our technology for use with stem cells, primary human cells and tissue and cell cryopreservation. This will create efficient protocols for each use as well as possible patent expansion based on the application. From there we will investigate other cell and tissue lines that can benefit from our technology."

About Lifeblood Medical, Inc.

Lifeblood Medical, Inc., headquartered in Freehold NJ, is a cell culture/biotech company whose goal is to enhance and extend the quality of life in the field of organ, cell and tissue preservation through the utilization of our proprietary solutions and by providing key reagents to the research community.

We distribute high quality serum and reagents to the research community at competitive prices. Our products include Serum (including US and Australia Fetal Bovine Serum), Serum Enhancers, Antibiotics and Specialty Media.

Our proprietary solution is considered platform enabling technology, with the potential to address a multitude of applications through all segments of the tissue, cell and organ transplant markets by way of its unique serum free, animal protein free and oxygen carrying properties. For the cell and tissue preservation market we offer LiforCell® and LiforLab®. For whole organ preservation, transportation and transplantation we offer LIFOR®. LIFOR® is currently undergoing clinical trials for the support of heart and kidney harvesting, transporting and reimplantation. FDA submission is anticipated later this year. Additional information is available online at

Source: Lifeblood Medical, Inc.

>>> Discuss This Story

Read at

comments powered by Disqus